{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:32:30Z","timestamp":1787682750831,"version":"build-2784847793"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the therapeutic effect of infliximab in patients with inflammatory vascular lesions due to Beh\u00e7et's disease (BD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seven patients with clinical evidence of severe vascular BD were analyzed: 3 patients with aortic involvement, 1 with recurrent venous thrombosis of the pelvic veins, 1 with recurrent venous and arterial thromboses of the thigh, and 2 with retinal vasculitis. Infliximab was initiated with 3\u20135 mg\/kg of body weight and infusions were repeated in intervals of 4 weeks as either first\u2010line therapy in 3 patients or add on after failure of conventional immunosuppression in the remaining 4. Ongoing immunosuppression consists of a various combination of azathioprine (n = 2), methotrexate (n = 3), cyclosporine (n = 3), and low\u2010dose glucocorticoids (n = 3).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Control of inflammation was seen 1\u20135 days after infliximab induction in all patients. C\u2010reactive protein level was reduced from a mean of 89 mg\/liter prior to infliximab to 9 mg\/liter thereafter. Vision increased rapidly in patients with retinal vasculitis. Vascular grafts remained patent. The inflamed and dissected aortic wall healed over a period of 6 months. Infliximab could be stopped in 2 patients; intervals could be extended in 4 to a maximum of 8 weeks. Infliximab and basic immunosuppression were well tolerated; no drug\u2010induced side effects were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Infliximab is effective in inducing and maintaining remission of vasculitic activity in patients with BD. The rapid effect together with excellent tolerability suggests that infliximab should be considered as a first\u2010line agent in severe vascular BD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.21557","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T14:14:31Z","timestamp":1323699271000},"page":"607-611","source":"Crossref","is-referenced-by-count":67,"title":["Beh\u00e7et's disease: Successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis"],"prefix":"10.1002","volume":"64","author":[{"given":"Sabine","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2006.12.004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080432"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108571"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.029"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-009-0990-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2010.09.002"},{"key":"e_1_2_6_8_2","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","journal-title":"Lancet"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1430-6"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27568"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel329"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283368099"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei257"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2004.09.018"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701747137"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1213-z"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.21557","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.21557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:22:43Z","timestamp":1759414963000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.21557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1002\/acr.21557"],"URL":"https:\/\/doi.org\/10.1002\/acr.21557","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]}}}